Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

First Patient Enrolled in Phase 3 Study for Hepatitis D Treatment

Summary by contagionlive.com
Bluejay Therapeutics’ investigational therapy, brelovitug, offers weekly self-administered injections and will be studied against the only approved treatment outside the US.

2 Articles

pharmatimes.compharmatimes.com

Bluejay begins phase 3 trial of brelovitug for hepatitis D

First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex

Read Full Article
contagionlive.comcontagionlive.com

First Patient Enrolled in Phase 3 Study for Hepatitis D Treatment

Bluejay Therapeutics’ investigational therapy, brelovitug, offers weekly self-administered injections and will be studied against the only approved treatment outside the US.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contagionlive.com broke the news in on Monday, September 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal